HomeALMRY • OTCMKTS
add
ALMIRALL S A Unsponsored ADR
Market news
Financials
Income Statement
Revenue
Net income
| (EUR) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 286.10M | 14.99% |
Operating expense | 157.80M | 12.55% |
Net income | 21.60M | 191.89% |
Net profit margin | 7.55 | 154.21% |
Earnings per share | — | — |
EBITDA | 70.80M | 35.11% |
Effective tax rate | 39.66% | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 374.40M | 19.12% |
Total assets | 2.40B | 3.85% |
Total liabilities | 895.80M | 7.80% |
Total equity | 1.50B | — |
Shares outstanding | 213.47M | — |
Price to book | 1.50 | — |
Return on assets | 3.56% | — |
Return on capital | 4.58% | — |
Cash Flow
Net change in cash
| (EUR) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | 21.60M | 191.89% |
Cash from operations | 26.40M | 12.82% |
Cash from investing | -19.80M | 77.55% |
Cash from financing | -9.30M | -5.68% |
Net change in cash | -2.70M | 96.33% |
Free cash flow | 18.91M | 130.10% |
About
Almirall, S.A. is a Spanish pharmaceutical company dedicated to medical dermatology, with headquarters in Barcelona, founded in 1944.
In 2023, the company generated total revenues of €898.8 million and was the leading European company in medical dermatology.
With approximately 1,904 employees, it has a direct presence in 20 countries through its 15 subsidiaries in Europe and the USA. Wikipedia
Founded
1944
Website
Employees
2,026
